Shire PLC (NASDAQ:SHPG) was downgraded by ValuEngine from a “buy” rating to a “hold” rating in a note issued to investors on Friday.

Other research analysts have also issued reports about the stock. Stifel Nicolaus decreased their price target on shares of Shire PLC from $250.00 to $245.00 and set a “buy” rating on the stock in a research note on Friday, June 9th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $216.00 price target (down from $239.00) on shares of Shire PLC in a research note on Friday, June 9th. Royal Bank Of Canada set a $221.00 price target on shares of Shire PLC and gave the company a “buy” rating in a research note on Thursday, May 18th. Cantor Fitzgerald set a $222.00 price target on shares of Shire PLC and gave the company a “buy” rating in a research note on Saturday, July 1st. Finally, BTIG Research reaffirmed a “buy” rating and issued a $242.00 price target on shares of Shire PLC in a research note on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and fourteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $220.08.

Shares of Shire PLC (NASDAQ SHPG) traded up 1.64% during mid-day trading on Friday, hitting $151.84. 1,173,432 shares of the company’s stock traded hands. The stock has a market cap of $45.23 billion, a P/E ratio of 67.94 and a beta of 1.60. Shire PLC has a 1-year low of $139.36 and a 1-year high of $209.22. The stock has a 50 day moving average price of $155.30 and a 200-day moving average price of $170.18.

Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $3.73 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.53 by $0.20. The firm had revenue of $3.75 billion for the quarter. Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. The company’s quarterly revenue was up 54.2% compared to the same quarter last year. During the same period in the prior year, the business posted $3.38 earnings per share. Equities research analysts anticipate that Shire PLC will post $14.93 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/01/shire-plc-shpg-downgraded-to-hold-at-valuengine.html.

Several hedge funds have recently made changes to their positions in SHPG. Maverick Capital Ltd. increased its stake in shares of Shire PLC by 19.9% in the second quarter. Maverick Capital Ltd. now owns 1,942,087 shares of the biopharmaceutical company’s stock worth $320,969,000 after buying an additional 322,610 shares in the last quarter. Glenview Capital Management LLC increased its stake in shares of Shire PLC by 69.7% in the second quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock worth $284,756,000 after buying an additional 707,500 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Shire PLC by 0.9% in the first quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock worth $268,773,000 after buying an additional 13,665 shares in the last quarter. Ameriprise Financial Inc. increased its stake in shares of Shire PLC by 14.7% in the second quarter. Ameriprise Financial Inc. now owns 1,510,227 shares of the biopharmaceutical company’s stock worth $249,577,000 after buying an additional 194,059 shares in the last quarter. Finally, BlackRock Inc. increased its stake in shares of Shire PLC by 4,217.7% in the first quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock worth $249,755,000 after buying an additional 1,400,275 shares in the last quarter. Institutional investors and hedge funds own 19.13% of the company’s stock.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (NASDAQ:SHPG)

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.